List of high-quality authors
Shengda Resources: Deyun Mining, a subsidiary, obtained a mining license
Shengda Resources announced that the company's holding subsidiary, Alu Korqin Banner Deyun Mining Co., Ltd. (hereinafter referred to as "Deyun Mining"), recently completed the conversion of prospecting rights to mining rights for lead-zinc polymetallic mines in Bayan Baolegh District, and obtained the "Mining License" issued by the Chifeng Municipal Bureau of Natural Resources.
Wanye Enterprise (600641.)SH): Plans to spend 2500 million yuan to 500 million yuan to repurchase shares].
Wanye Enterprise announced that the company intends to repurchase shares in order to maintain the company's value and shareholders' rights and interests, and the shares repurchased by the company will be used for follow-up in accordance with relevant regulations. The total amount of repurchase funds shall not be less than RMB 2500 million yuan (inclusive) and not more than 500 million yuan (inclusive), and the repurchase price does not exceed 19 yuan9 yuan shares (inclusive).
Fuxiang Pharmaceutical: Xiangtai Science obtained the approval notice of the marketing application of chemical raw materials].
Fuxiang Pharmaceutical announced that recently, Jiangxi Xiangtai Life Science Co., Ltd., a wholly-owned subsidiary of Jiangxi Fuxiang Pharmaceutical Co., Ltd., received the "Notice of Approval of the Marketing Application for Chemical APIs" for tazobactam sodium API approved and issued by the State Drug Administration.
Sunflower Pharmaceutical: Fexofenadine hydrochloride oral suspension was accepted for marketing authorization].
Sunflower Pharmaceutical announced that Harbin Sunflower Pharmaceutical, a wholly-owned subsidiary of the company, recently received the "Notice of Acceptance" issued by the State Drug Administration on the application for registration and marketing authorization of fexofenadine hydrochloride oral suspension.
Mabwell: Obtained FDA approval for the new drug investigational trial application of 7MW3711 for injection
Mabwell announced that the new drug clinical trial application of 7MW3711 for injection has been approved by the FDA.